• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

FDA approves Abecma as ‘earlier line of therapy’ for triple-class exposed multiple myeloma

by | Apr 5, 2024 | Uncategorized

The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.This approval expands the indication for idecabtagene...

FDA Approves Abecma for Pretreated R/R Multiple Myeloma

by | Apr 5, 2024 | Uncategorized

Source: CureToday articles The Food and Drug Administration approved Abecma for adults with relapsed or refractory multiple myeloma who have received two or more previous lines of therapy. Read More

Tracking a Mystery in Non-Secretory Myeloma

by | Apr 3, 2024 | Uncategorized

Source: CureToday articles There is no difference in treatment for non-secretory multiple myeloma and multiple myeloma, an expert told CURE®. Read More

I Can’t Help Wondering How My Multiple Myeloma Came to Be

by | Apr 3, 2024 | Uncategorized

Source: CureToday articles Of everything I’ve ever done, I wonder how my multiple myeloma came to be. Read More

March is Myeloma Awareness Month

by | Mar 21, 2024 | Uncategorized

Source: CureToday articles Post Content Read More

The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease

by | Mar 20, 2024 | Uncategorized

Nat Commun. 2024 Mar 19;15(1):2458. doi: 10.1038/s41467-024-46594-0. ABSTRACT Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic...
« Older Entries
Next Entries »

Recent Content

  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
  • FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
  • Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT